



Monteris® Medical Press Release

April 26 2013

Monteris® Medical First-In-Humans Trial Published

MINNEAPOLIS

Data supports the use of the NeuroBlate® System for the MRI guided ablation of brain tumors

Monteris Medical announced that the First-In-Humans clinical trial of the NeuroBlate® System for neurosurgical ablation has been published in the Journal of Neurosurgery (www.thejns.org – publish before print). This study was a thermal dose-escalation trial to assess the safety and efficacy of the NeuroBlate System to treat recurrent Glioblastoma Multiforme (GBM) brain tumors. "Although not a large trial, it is significant as a foundation on which to build the clinical data needed for broad technology adoption," said Dr. Andrew Sloan, Director of the Brain Tumor & Neuro-Oncology Center, Vice Chairman of Neurosurgery and holder of the Peter D. Cristal Chair of Neurosurgical Oncology at University Hospitals-Case Medical Center and a Principal Investigator in the trial. "Furthermore, this is the first contemporary report of a trial using laser interstitial thermal therapy for gliomas, which are a particularly difficult type of brain tumor to treat and have a very poor prognosis".

Ten patients with recurrent or progressive GBM who had failed standard therapy (radiotherapy with or without chemotherapy) and were deemed to have "inoperable recurrent GBM" were enrolled in the trial. The patients were divided into three groups defined by the amount of laser energy (dose) delivered to the tumor with the NeuroBlate System. "The median survival time of 316 days seen in this cohort of patients is encouraging, as compared to the 90-150 day median survival typically observed for recurrent GBM's" stated Dr. Gene Barnett, Professor and Director of the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Vice-Chair of Neurosurgery and Rose Ella Burkhardt Chair in Neuro-Oncology Research at Cleveland Clinic. "These patients not only have a poor prognosis, but have limited treatment options. We believe that the NeuroBlate System will be an important tool for Neurosurgeons and allow us to treat patients that might otherwise have few options." Dr. Barnett was the Principal Investigator in the trial and is a Consulting Medical Director for Monteris.

The full article is available on the Journal of Neurosurgery website, www.thejns.org.

About Monteris® Medical

Monteris Medical is a privately held company developing devices for minimally-invasive, MR-guided neurosurgery. Monteris markets the NeuroBlate System for controlled, volumetric ablation of brain lesions. Monteris also offers the AXiiiS Stereotactic Miniframe; a single use platform for image-guided trajectory alignment, and the AtamA Stabilization System for MR based procedures requiring versatile head fixation.

www.monteris.com

Monteris Contact:

John Schellhorn

Phone: 763-253-4710

Email: jschellhorn@monteris.com

